Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.80 and traded as high as $1.69. Cortexyme shares last traded at $1.62, with a volume of 2,176,771 shares.
Cortexyme Stock Performance
The company has a market cap of $48.84 million, a P/E ratio of -0.55 and a beta of 1.40. The firm has a 50 day moving average price of $0.78 and a 200-day moving average price of $0.80.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Articles
- Five stocks we like better than Cortexyme
- Want to Profit on the Downtrend? Downtrends, Explained.
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- 3 Tickers Leading a Meme Stock Revival
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
